These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8434556)

  • 1. The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST).
    Walldius G; Regnström J; Nilsson J; Johansson J; Schäfer-Elinder L; Moelgaard J; Hådell K; Olsson AG; Carlson LA
    Am J Cardiol; 1993 Feb; 71(6):15B-19B. PubMed ID: 8434556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
    Walldius G; Carlson LA; Erikson U; Olsson AG; Johansson J; Mölgaard J; Nilsson S; Stenport G; Kaijser L; Lassvik C
    Am J Cardiol; 1988 Jul; 62(3):37B-43B. PubMed ID: 3293415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
    Regnström J; Walldius G; Nilsson S; Elinder LS; Johansson J; Mölgaard J; Holme I; Olsson AG; Nilsson J
    Atherosclerosis; 1996 Sep; 125(2):217-29. PubMed ID: 8842353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
    Walldius G; Erikson U; Olsson AG; Bergstrand L; Hådell K; Johansson J; Kaijser L; Lassvik C; Mölgaard J; Nilsson S
    Am J Cardiol; 1994 Nov; 74(9):875-83. PubMed ID: 7977117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro.
    Regnström J; Walldius G; Carlson LA; Nilsson J
    Atherosclerosis; 1990 May; 82(1-2):43-51. PubMed ID: 2360919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
    Johansson J; Olsson AG; Bergstrand L; Elinder LS; Nilsson S; Erikson U; Mölgaard J; Holme I; Walldius G
    Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1049-56. PubMed ID: 7627695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
    Reaven PD; Parthasarathy S; Beltz WF; Witztum JL
    Arterioscler Thromb; 1992 Mar; 12(3):318-24. PubMed ID: 1547191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia.
    Masana L; Bargalló MT; Plana N; LaVille A; Casals I; Solà R
    Am J Cardiol; 1991 Oct; 68(9):863-7. PubMed ID: 1927944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits.
    Bocan TM; Mueller SB; Brown EQ; Uhlendorf PD; Mazur MJ; Newton RS
    Exp Mol Pathol; 1992 Aug; 57(1):70-83. PubMed ID: 1397193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of lipoprotein lipids, dietary fat and smoking on macrophage degradation of native and oxidized low density lipoprotein.
    Regnström J; Walldius G; Hådell K; Johansson J; Holme I; Olsson AG; Nilsson J
    Atherosclerosis; 1994 Sep; 110(1):13-23. PubMed ID: 7857366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose colestipol plus probucol for hypercholesterolemia.
    Dujovne CA; Chernoff SB; Krehbiel P; Jackson B; DeCoursey S; Taylor H
    Am J Cardiol; 1984 Jun; 53(11):1514-8. PubMed ID: 6375337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression.
    Baldassarre D; Franceschini G; Peruzzotti G; Brusoni B; Sirtori CR
    J Cardiovasc Pharmacol; 1997 Dec; 30(6):784-9. PubMed ID: 9436818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
    Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
    Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?
    Sasahara M; Raines EW; Chait A; Carew TE; Steinberg D; Wahl PW; Ross R
    J Clin Invest; 1994 Jul; 94(1):155-64. PubMed ID: 8040256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probucol treatment decreases serum concentrations of diet-derived antioxidants.
    Elinder LS; Hådell K; Johansson J; Mølgaard J; Holme I; Olsson AG; Walldius G
    Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1057-63. PubMed ID: 7627696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxidative stress and superoxide generation.
    Keaney JF; Xu A; Cunningham D; Jackson T; Frei B; Vita JA
    J Clin Invest; 1995 Jun; 95(6):2520-9. PubMed ID: 7769097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probucol in hypercholesterolemia. A double blind study.
    Riesen WF; Keller M; Mordasini R
    Atherosclerosis; 1980 Jun; 36(2):201-7. PubMed ID: 7406949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol.
    Mao SJ; Yates MT; Parker RA; Chi EM; Jackson RL
    Arterioscler Thromb; 1991; 11(5):1266-75. PubMed ID: 1911712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pravastatin vs. probucol in the treatment of hypercholesterolemia. A double-blind study].
    Sienra-Pérez JC; Lerman-Garber I; Ahumada-Ayala M; Castañón-Romo C; Cardoso-Saldaña G; Laguna-Castellanos M; Posadas-Romero C
    Arch Inst Cardiol Mex; 1991; 61(4):365-73. PubMed ID: 1953212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
    Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
    Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.